Bio-Thera Solutions began a phase 1 trial for its mepolizumab biosimilar candidate; Biocon Biologics licenses out 2 biosimilars to Yoshindo; and Alvotech and STADA Arzneimittel launch Hukyndra, an adalimumab biosimilar, in Switzerland. Testing for Mepolizumab Biosimilar Begins Bio-Thera Solutions began a phase 1 study for a biosimilar candidate referencing Nucala (mepolizumab). The study would assess […]
The post Mepolizumab Study; New Licensing Deal; Hukyndra Launches in Switzerland appeared first on The Black Chronicle.
